FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage ...

Reports

4

Domains carrying it

4

First reported

19 August 2026

Latest report

1 September 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 19 August 2026Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever ...ir.ultragenyx.com
2. 20 August 2026Recon: FDA approves Ultragenyx gene therapy for glycogen storage disorderraps.org
3. 1 September 2026FDA Approves Ultragenyx's GENGLYCOS™ Gene Therapy for GSDIajdsupra.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier ...2 reports · 2 domains · 1 September 2026
• Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome2 reports · 2 domains · 3 September 2026
• Amylyx declares late-stage win with a GLP-1 antagonist in its post-ALS reset3 reports · 3 domains · 18 August 2026
• FDA authorizes first dual glucose-ketone monitor for children as young as 22 reports · 2 domains · 26 August 2026
• Lilly, with new data, to seek FDA approval of obesity drug retatrutide3 reports · 3 domains · 4 August 2026
• U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for ...2 reports · 2 domains · 20 August 2026

◆ Share

◆ Evidence

4 reports · 4 domains

• FDA Approves Ultragenyx's GENGLYCOS™ Gene Therapy for GSDIajdsupra.com · 1 September 2026
• Recon: FDA approves Ultragenyx gene therapy for glycogen storage disorderraps.org · 20 August 2026
• FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage ...fda.gov · 19 August 2026
• Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever ...ir.ultragenyx.com · 19 August 2026